"The decision for which laser to use in your institution should be left up to the urologist and the hospital system," says Margaret A. Knoedler, MD. Data presented at the 2025 American Urological ...

In an interview with Urology Times®, John L. Gore, MD, MS, FACS, shares the background and key findings from the study, “Radical Cystectomy Versus Bladder-Sparing Therapy For Recurrent High-Grade ...

In an interview with Urology Times®, Jason M. Hafron, MD, CMO, discusses his talk, “Barriers in Recruiting and Running Effective Clinical Trials in Independent Practices,” which was presented at the ...

Social media platforms are major sources of prostate cancer misinformation, affecting patient education and care provider relationships. Misinformation is often spread by unlicensed individuals posing ...

TARA-002 demonstrated a 100% high-grade complete response in BCG-unresponsive patients at 6 months, with a 76% CR in BCG-naïve patients. The agent acts as a broad-spectrum immune potentiator, ...

Sasanlimab plus BCG significantly improved EFS compared to BCG alone in high-risk NMIBC patients, with a 32% lower risk of EFS events. The study involved 1055 BCG-naïve patients, focusing on EFS, ...

Higher levels of drinking water contaminants are associated with increased kidney stone burden and recurrence, independent of socioeconomic factors. The study analyzed over 1100 California residents, ...

A recent study in JCO Oncology Practice found that in the oncology medical literature, women had a 15% lower Altmetric Attention Score (AAS) as first authors, and an 8% lower (AAS) in the last author ...

“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP. When communicating her patients, Anna Myers, CNP, places great ...

Clarius Prostate AI reduces prostate volume measurement time from minutes to seconds, enhancing clinical efficiency. The application integrates with Clarius handheld ultrasound scanners and calculates ...

The Break Wave System offers a noninvasive, anesthesia-free option for kidney stone treatment using low-pressure ultrasound waves. The SOUND trial enrolled 64 patients to assess the system's safety ...

A panelist discusses how clinicians should weigh the decision between enzalutamide and darolutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by considering each drug’s ...